Research progress in signalling pathway in diabetic nephropathy

E-ISSN： 1099-0895|31|3|221-233

ISSN： 1520-7552

Source： DIABETES/METABOLISM: RESEARCH AND REVIEWS (ELECT), Vol.31, Iss.3, 2015-03, pp. : 221-233

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Preventing diabetic nephropathy: an audit

By Hansen H. P. Lund S. S. Rossing P . Tarnow L. Nielsen F. S. Jensen T. Parving H.-H.

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 61, Iss. 6, 2001-09 ,pp. : 471-477

Informa Healthcare

Access to resources Recommend Favorite

Metabolic Phenotyping of Diabetic Nephropathy

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 5, 2013-11 ,pp. : 566-569

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epigallocatechin‐3‐Gallate Attenuates Oxidative Stress and Inflammation in Obstructive Nephropathy via NF‐κB and Nrf2/HO‐1 Signalling Pathway Regulation

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 117, Iss. 3, 2015-09 ,pp. : 164-172

John Wiley & Sons Inc

Access to resources Recommend Favorite

Diabetic nephropathy research in China: Data analysis and review from the National Natural Science Foundation of China中国糖尿病肾病研究现状：对中国国家自然科学基金数据的回顾性分析

JOURNAL OF DIABETES, Vol. 7, Iss. 3, 2015-05 ,pp. : 307-314

John Wiley & Sons Inc

Access to resources Recommend Favorite

Fucoidan exerts protective effects against diabetic nephropathy related to spontaneous diabetes through the NF-κB signaling pathway in vivo and in vitro

International Journal of Molecular Medicine, Vol. 35, Iss. 4, 2015-01 ,pp. : 1067-1073

Spandidos Publications

Access to resources Recommend Favorite